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Abstract
Listeria monocytogenes is a gram-positive bacteria and human pathogen widely used in
cancer immunotherapy because of its capacity to induce a specific cytotoxic T cell response
in tumours. This bacterial pathogen strongly induces innate and specific immunity with the
potential to overcome tumour induced tolerance and weak immunogenicity. Here, we pro-
pose a Listeria based vaccination for melanoma based in its tropism for these tumour cells
and its ability to transform in vitro and in vivomelanoma cells into matured and activated
dendritic cells with competent microbicidal and antigen processing abilities. This Listeria
based vaccination using low doses of the pathogen caused melanoma regression by apo-
ptosis as well as bacterial clearance. Vaccination efficacy is LLO dependent and implies the
reduction of LLO-specific CD4+ T cell responses, strong stimulation of innate pro-inflamma-
tory immune cells and a prevalence of LLO-specific CD8+ T cells involved in tumour regres-
sion and Listeria elimination. These results support the use of low doses of pathogenic
Listeria as safe melanoma therapeutic vaccines that do not require antibiotics for bacterial
removal.
Introduction
Coley reported for the first time cancer therapies based on the use of bacteria after observation
of the tumour regression in a patient after bacterial infection [1]. During the early development
of bacterial-based anticancer therapies, different anaerobic bacteria were used that can prolifer-
ate in a hypoxic environment such as that of tumours. Some examples are Clostridium novyi,
Bifidobacteria, Streptococcus pyogenes or Vibrio cholera. The use of bacteria as anticancer
agents was followed by antibiotic treatment to control the infection. However, current
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bacterial-based anticancer therapies use attenuated strains of Salmonella and Listeria monocy-
togenes (LM) expressing specific antigens to target them to tumours and reduce tumour burden
[2,3].
Listeria monocytogenes based vaccine vectors with attenuated strains show high efficiency
against several tumours such as neuroglioma, hepatocellular carcinoma, cervical, prostate, and
breast cancers, with a bacterial burden 500-fold higher than the classical doses used with patho-
genic LMWT [4,5]. The efficiency of Listeria based vaccines depends on the ability of the bacte-
ria to induce a strong innate and T-cell based immunity playing an important role CD11c+
dendritic cells (DCs) together with the pathogen’s capacity to overcome tolerance to self-anti-
gens such as tumour antigens [6].
Melanomas are malignant forms of melanocytes and common skin cancers, with an inci-
dence of 2%. They are particularly aggressive in highly photosensitive skin types. In our institu-
tion, the rate of incidence of melanoma increased by 3% in the last 2 years, becoming the most
prevalent cancer among young women under the age of 40 years [7]. Melanoma is a low immu-
nogenic tumour characterized by the aberrant expression of MHC class II molecules that
might present melanoma-associated antigens to specific CD4+ T cells [8]. However, melanoma
MHC class II expression correlates with metastatic disease and poor survival [9] and the mela-
noma specific CD4+ T cells appeared as tumour tolerogenic. Murine melanoma models that
mimic the aggressive behaviour of metastatic melanoma, such as B16F10 cells, have been devel-
oped, and similar to humans, they also express MHC class II molecules [10].
Bacterial infection in melanoma or melanocytes has not been investigated in detail, and
only rare infections have been reported such as non-tuberculosisMycobacterium infection or
abscesses of Salmonella enterica at the site of melanoma metastasis [11–13]. Several cases of cu-
taneous listeriosis in adults have also been reported; suggesting that infection of melanocytes
with Listeria is possible [14], although LM infection of melanoma or melanocytes is not well
understood. Furthermore, most cases of neonatal listeriosis show diffuse skin lesions. Here, we
hypothesized that Listeria tropism for melanoma might cause activation of the anti-melanoma
immune response, blocking tumour progression. In the present study, we test this hypothesis
performing a detailed analysis of the phagocytic abilities of melanoma cells after Listeria infec-
tion and propose a Listeria based vaccination for experimental melanoma.
Materials and Methods
Cells, recombinant proteins and peptides
Murine melanoma B16F10 cells were a gift from B. Alarcon and acquired from ATCC, human
melanoma cell lines A-375 andMel-H0, were a gift fromM.D Boyano-Lopez and acquired from
ATCC, J-774 murine macrophages and CHO cells were acquired from ATCC. Bone-marrow-de-
rived dendritic cells (BMDC) were obtained from femurs of C57BL/6, Balb/c or CD-1 mice dif-
ferentiated with 25 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) for 7
days as described [15]. Murine embryonic fibroblasts were cultured after thawing as previously
described [16]. On day 7, we performed a positive selection of CD11c+-BMDC cells using mag-
netic beads and MACS separation columns (Miltenyi Biotech Inc., Auburn, CA) [15]. E. coli
strain BL21 expressing large quantities of His-fusion recombinant LLO protein (LLOrec) was pro-
vided byD.A. Portnoy. F. Roncal synthesized LLO296–304 and LLO190–201 peptides (CNB, CSIC,
Madrid) followed by HPLC andMass Spectrometry using a MALDI-TOF Reflex IV mass spec-
trometer (Bruker Daltonics, Bremen, Germany). Peptide purity was> 95% after HPLC. B16F10
cells (2 x 109) were homogenized as previously described for J-774 cells and precipitated with
TCA and washed with PBS to obtain a B16F10 extract (MELext) (1 mg/ml).
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Bacteria. L.monocytogenes
10403S strain (LMWT) and the hly-deficient LM mutant (LMΔLLO, DPL-2161 strain) were ob-
tained from D.A. Portnoy (University of California, Berkeley, CA, USA) and green fluorescent
protein (GFP)–LM variant of LMWT strain DH-L1039 (GFP-LMWT) from D.E. Higgins (Har-
vard Medical School, Boston, MA, USA).
Kinetic infection assays
CD11c+-BMDC, A-375, Mel-H0 and B16F10 cells were infected with LMWT or LMΔLLO at a
ratio of 10:1 (bacteria: cells) for different times (0, 4, 8 or 16 h) as described [15]. J-774, MEF
and CHO cells were infected as previously reported [16]. Colony forming units (CFU) were ex-
amined in blood agar plates and results are the mean ± SD.
Replication indexes of LM strains in melanoma and BMDC
Replication indexes (RIs) were calculated in CD11c+-BMDC, A-375, Mel-H0 and B16F10 cells
infected as ratios of CFU at 16 h to CFU at 0 h ± SD of triplicates as reported [16, 17]. RI values
higher than 25, represent a rapid LM proliferation and poor bactericidal abilities of the cells.
Phagocytic rates corresponded to bacteria internalization rates at 0 h.
Phagosome isolation and cytosolic fractions
CD11c+-BMDC, A-375, Mel-H0 and B16F10 cells were infected for 1 hour and homogenized
in HBE buffer (250 mM sucrose, 0.5 mM EGTA, 20 mMHEPES-KOH, pH 7.2) to obtain post-
nuclear supernatants (PNS). Phagosomes were isolated from an aliquot of PNS into a 20% su-
crose gradient as described [16, 17]. An additional PNS was used to estimate the percentage of
total internalized bacteria expressed as CFU. The percentages of phagosomal and cytosolic bac-
teria were calculated according to the following ratio, PNS—phagosomal numbers/PNS × 100,
as described [16, 17].
Phagosome western blotting and immunoprecipitations
Phagosomes isolated from BMDCs, B16F10, J-774, MEF or CHO cells infected with LMWT for
20 min, were solubilized and CFU analysed in blood agar plates. MHC-II and Rab5a molecules
were detected by western blotting and the two forms of LLO bound to MHC class II molecules,
LLOintact and processed LLO1–491 forms were detected after immunoprecipitation with anti-
MHC-II antibodies followed by western-blot with rabbit anti-LLO antibody as reported [17].
Confocal microscopy
B16F10 and BMDC cells were infected with GFP-LM for 1 h, washed, fixed in 3% paraformal-
dehyde and permeabilized with PBS-0.05% Triton X-100 as reported [15–17]. Confocal mi-
croscopy imaging was performed with a Nikon A1R confocal microscope.
B16F10 induction of carcinomatous peritonitis and LM vaccination
C57BL/6 female mice (n = 5) were inoculated in the peritoneal cavity (i.p) with 5 × 105 B16F10
cells for 7, 15 or 23 days. For LMWT vaccinations, mice inoculated i.p with B16F10 for 7 days
were next infected i.p with 5 × 103 GFP-LM (CFU/mice) (n = 5) for 5 days to analyse LM in-
nate and specific immunity. Mice were bled before sacrifice and sera stored at −80°C to mea-
sure cytokines by FACS analysis. Spleens, peritoneal melanoma and lungs were recovered and
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photographed. Spleens and melanoma were further processed for FACS analysis and an aliquot
plated into blood-agar plates to count CFU.
Immunohistochemistry
Mice were sacrificed on days 7, 15 and 23 after melanoma inoculation. The most common met-
astatic organs (liver, spleen, kidney, adrenal glands, liver and lungs) were resected, sectioned,
and fixed by immersion in 4% formaldehyde for 24 h. Organs were subsequently embedded in
paraffin and cut at 3-μm thickness for histological analysis. Different sections (stained with he-
matoxylin-eosin) of each organ were analysed by two independent pathologists. For immuno-
histochemical analysis of lymphocyte markers, EnVision technology (Dako) was used. Samples
were boiled in target retrieval solution buffer (pH 6 for CD23, pH 8 for the rest) for 20 min,
subsequently cooled in distilled water and 1×PBS. Next, the sections were incubated with
ready-to-use primary monoclonal antibodies (Dako) against CD4 (clone 4B12), CD8 (clone
c8/144B), CD23 (clone DAK-CD23), CD45 (clone 2B11 + PD7/26), CD56 (clone 123C3) and
CD68 (clone KP1). The antigens were visualized using biotinylated antibodies and streptavidin
conjugated with horseradish peroxidase (EnVision Mouse HRP, Dako). Diaminobenzidine
(DAB, Dako) was used as the chromogen. Antigen concentrations were all determined based
on the percentage and intensity of tumour cells showing positive staining.
FACS analysis of spleens, melanoma, intracellular IFN-gamma staining
and cytokine measurements
Cell surface markers of J-774 macrophages, BMDCs or B16F10 melanoma infected or not with
different LM strains (LMWT, GFP-LMWT or LMΔLLO) or spleens and recovered melanoma from
mice treated with B16F10 and infected with the above mentioned LM strains were analysed by
FACS for the following markers: CD4-PE, CD8α-PE, CD49b-PE, F4/80-PE, CD11b-APC,
CD11c-PE, MHC-II-APC, CD40-PE, CD83-APC, CD86-V450 and iNOS/type II-FITC. Melano-
ma cells frommice were also analysed for apoptosis by FACS analysis using Annexin-V-APC
and 7-AAD (BD-Biosciences). Mice sera or supernatants of B16F10 cells infected or not with
LMWT for 24 hours were used to quantify cytokines using the CBA kit (Becton Dickinson, Palo
Alto, CA, USA). Samples were analysed in triplicate and results were expressed as the mean ± SD
of two separate experiments. For measuring of intracellular IFN-γ, spleen cells were cultured in
96-well plates (5 x 106 cells/ml) and stimulated with recombinant LLO (0.1 μg/ml), B16F10 ex-
tract (50 μg/ml) (MELext), LLO190–201 (50 μM) or LLO296–304 peptides (50 μM) for 5 h in the pres-
ence of brefeldin A [15, 17]. Next, cells were surface labelled for CD4 or CD8, fixed and
permeabilized with cytofix/cytoperm kit to measure intracellular IFN-gamma (BD Biosciences).
After sample acquisition, data were gated for CD4+ or CD8+ events, and the percentages of these
cells expressing IFN-gamma were determined according with the manufacturer’s recommenda-
tions. Results were corrected according to the percentages of total CD4+ or CD8+ positive cells.
Data were analysed using FlowJo software (Treetar, Ashland, OR).
Frequencies of LLO-peptide specific CD8+ T cells
To confirm the frequency of LLO296–3049-specific CD8 T cells producing IFN-gamma, we used
recombinant soluble dimeric mouse H-2Kb:Ig fusion protein following the instructions of the
manufacturer (DimerX I; BD Bioscience). LLO296–304 peptide (40 μM) was pre-incubated with
PE-conjugated H-2Kb:Ig (1 μM) in PBS, at 37°C for 16 h as previously described [15]. Spleno-
cytes (2 × 107 cells/ml) were incubated with IFN-gamma and CD8 antibodies and the staining
cocktail mix described above for 10 min at 4°C. Percentages of CD8+ gated cells were expressed
as the mean ± SD of triplicates (P< 0.05). Data were analysed using FlowJo software.
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Measurement of NO production
B16F10 and BM-DC were infected with LM or not and assayed for NO production as previous-
ly reported [18].
B16F10 subcutaneous tumour model and LM vaccination
Newborn C57BL/6, Balb/c or CD-1 mice of 2 days old (n = 10) were inoculated in the back sub-
cutaneously (s.c) with 1 x 105 B16F10 cells for 7 days to develop a measurable (4–6 mm) tu-
mour. For LMWT vaccinations, mice inoculated s.c with B16F10 for 7 days were next infected
s.c with 1 x103 LMWT (CFU/mice) (n = 10) for 5 days. Mice were sacrificed and tumours
weighted and sizes measured with a calliper and photographed to obtain images. Values shown
for tumour size (mm) were the mean ± SD of three different experiments.
Statistical analysis
Student’s t test was used for statistical analysis and analysis of variance (ANOVA) for cytokine
measurements. Data were analysed using FlowJo software (Treestar, Ashland, OR). P 0.05
was considered significant. GraphPad software was used for graphic presentation.
Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the Spanish Ministry of Science, Research and Innova-
tion. The Committee on the Ethics of Animal Experiments of the University of Cantabria ap-
proved this protocol (Permit Number: 2012/06) that follows the Spanish legislation (RD 1201/
2005). All surgery was performed under sodium pentobarbital anaesthesia, and all efforts were
made to minimize suffering.
Results and Discussion
Coley’s observations that a neck cancer patient recovered after infection with erysipelas initiat-
ed the use of bacteria and their toxins to treat end stage cancers [3]. However, pathogenicity
and toxicity are important concerns limiting the broad clinical application of bacteria as anti-
cancer agents. In this regard, the adjuvant features of LM involve its ability to target and acti-
vate DCs and its dual intracellular distribution in phagosomes and cytosol, which allows the
activation of LM specific CD4+ and CD8+ T cells. However, two additional LM characteristics
seemed also relevant to target tumour cells [5] and to live under hypoxic conditions. Attenuat-
ed LM strains on a truncated form of listeriolysin O (LLO) fused to tumour antigens appeared
as promising vaccines for cervical and breast cancer [4,5]. These cancer vaccines exerted their
effect through out the killing of tumour cells by CD8+ cytotoxic responses to tumour antigens.
However, there are other mechanisms by which Listeria-based cancer vaccines show their ac-
tions, independent of tumour antigens. Here, we present a dramatic effect of LMWT vaccination
on an experimental melanoma model with poor immunogenicity, the B16F10 induction of
cancerous peritonitis. We provide evidence of melanoma growth reduction after LMWT vacci-
nation and transformation of tumour cells into activated dendritic cell phenotypes that acti-
vates Listeria-specific CD8 T cell responses and innate pro-inflammatory responses that in
turns eliminated the pathogen.
In vitro Listeria induced transformation of melanoma into dendritic cells
Melanoma is one of the fastest growing cancers in the world, and surgery is the best available
therapy for this malignancy both during the early developmental stages and in advanced
Listeria Vaccination Causes Melanoma Regression
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metastatic melanoma. Therefore, alternative measures are needed as the one proposed in this
study using low doses of pathogenic LMWT as a vaccination therapy. This therapy is based in
the high tropism of LM for melanoma [5,19] and the transformation of these tumour cells into
dendritic-like cell phenotypes functioning as competent APC.
We first observed that murine or human melanoma cell lines infected with pathogenic
LMWT, transformed these malignant melanocytes into professional antigen presenting cells,
APC, with a phenotype and function analogous to those of skin DCs, also known as Langer-
hans cells. In this regard, LMWT murine showed a characteristic exponential proliferation in
murine (B16F10) or human melanoma cell lines (A-375 or Mel-H0) (black circles in Fig. 1A)
and high phagocytic rates (left plot of Fig. 1B). The LM hly-deficient strain, LMΔLLO, which has
a gene deletion that renders it unable to escape from phagosomes, did not replicate in any mel-
anoma cell line (open circle plots of Fig. 1A) and suggested that melanoma posed listericidal ca-
pacity. In fact, pathogenic LMWT presented high replication indexes, RI, (RI> 25) in
melanoma and BMDC and the majority of the bacteria localized in the cytosol, 65–68% of
LMWT (middle and right plots of Fig. 1B). APC such as BMDC or melanoma showed medium
ranges of listericidal abilities since LMΔLLO mutants showed no intracellular growth (Fig. 1A)
[15], low RI values (RI< 1) (white bars in middle plot of Fig. 1B) and almost no bacteria local-
ized in the cytosol (white bars in right plot of Fig. 1B). However, J-774 macrophages are APC
with higher listericidal abilities since LMΔLLO mutants become degraded (RI< 0.1) (S1A Fig.).
On the other side, non-APC cell types such as mouse embryonic fibroblasts (MEF) or the ovar-
ian CHO tumour cells lacked listericidal abilities since both LMWT and LMΔLLO showed expo-
nential intracellular growth as previously reported [16] (S1A Fig.). These results strongly
suggested that melanoma function as professional phagocytes. Next, we verified APC function
examining the antigen processing compartments (MIIC) competency. Melanoma cells infected
with LMWT, showed phagosomal-like structures with significant co-localization of green-fluo-
rescent bacteria, GFP-LMWT and MHC-II molecules (yellow fluorescence in Fig. 1C), reflecting
high MIIC competency. Similarly, purified phagosomes of melanoma and BMDC presented
high levels of classical MIIC markers [16, 17] such as the endosomal-phagosomal regulator
Rab5a, stable a/b MHC-II molecules and significant amounts of LLO1–491 processed forms that
bound to MHC class II molecules (western blots in Fig. 1C and S1B Fig.). They also presented
lysosomal enzymes involved in LLO processing such as cathepsin-D (S1B Fig.) and low CFU
values confirming their microbicidal capacities (CFU Phago values below western blots of
Fig. 1C) [16–18]. J-774 macrophages presented almost all MIIC markers except for low levels
of cathepsin-D, while non-APC cells as MEF or CHO exclusively showed the MIIC marker
Rab5a, indicating very low MIIC competency (S1B Fig.) [15, 18].
Since the characteristic phenotype of B16F10 melanoma, namely MHC-
II+CD11c+/-CD40+/-CD83+/-CD86+/-CD11b-CD8α-F4/80-Gr-1- (white bars in the right plot of
Fig. 1D) [20], also resembles that of immature DCs [21], we next evaluated LMWT effect on cell
surface markers. LMWT transformation of melanoma resulted in a shift to a phenotype charac-
teristic of matured DCs, namely MHC-II++CD11c++CD40+CD83+CD86+CD11b-CD8α+i-
NOS
+
F4/80-Gr-1- (black bars in Fig. 1D and Table 1). This melanoma transformation required
LLO since LMΔLLO mutants caused no change in the phenotype (grey bars in Fig. 1D). The
strategy was as follows; first we selected on the FACS plots of non-infected melanoma
(B16F10-NI in Fig. 1D-FACS plots on right), the single positive MHC-II cells. Using same pa-
rameters, we selected on FACS plots of melanoma-infected cells (B16F10-LMWT in Fig. 1D-
FACS plots on the right), the single positive MHC-II cells. Next, we selected the double positive
MHC-II and CD11c or CD40 or CD83 or CD86 cells (last arrow sequence in B16F10-LMWT
plots in Fig. 1D-FCAS plots on the right). Infection of human melanoma A375 and Mel-H0
with LMWT also shifted the phenotype towards an activated DC-like phenotype characterized
Listeria Vaccination Causes Melanoma Regression
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Fig 1. Listeria induced transformation of melanoma into dendritic cells. A, Kinetic analysis of BMDC, murine (B16F10) and human (A-375 and Mel-H0)
melanoma cells infected with different LM strains (LMWT, LMΔLLO). Results are expressed as CFU (mean ± SD) obtained with triplicate samples from three
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by HLA-DR+CD11c+CD40+CD83+CD86+CD11b- cells [22, 23] following the same strategy as
for B16F10 cells (data not shown). Moreover, melanoma infected with LMWT produced high
levels of the pro-inflammatory cytokines MCP-1, TNF-α, and IL-12 (Fig. 1E) as well as high
production of nitric oxide, NO (Table 1), a classical listericidal reactive intermediate [18] also
involved in tumour regression. We previously reported this characteristic DC phenotype and
cytokine pattern on a dendritic-based vaccine for listeriosis that triggers a pro-inflammatory
CD8+ T cell based immune response [15]. LMWT infection of other APC such as J-774 macro-
phages does not cause transformation into DC-like phenotypes (S1 Fig., panel C), either pro-
duction of the pro-inflammatory cytokines above-mentioned [15, 17]. In brief, LMWT infection
transformed melanoma into matured DC with competent APC functions and potential for
tumour therapies.
Listeria therapy of melanoma causes tumour regression by apoptosis
and bacterial clearance
To evaluate the potential of a LMWT based therapy for melanoma, we set up a model of carci-
nomatous peritonitis induced by inoculation of B16F10 melanoma into C57BL/6 mice perito-
neum for different times, 7, 15 or 23 days. The progression of melanoma in this model was as
follows, after 7 days of melanoma inoculation, there is an infiltrate of tumour cells in the
Table 1. Listeria infection of melanoma induces nitric oxide and iNOS expression.
CONDITIONa B16F10-NI B16F10-LMWT B16F10-LMWT BMDC-NI
NO productionb 0.5 ± 0.02 7.5 ± 0.2 0.6 ± 0.01 8.2 ± 0.5
APC-markersc APC-markers APC-markers APC-markers APC-markers
CD11c+ 22 ± 0.2 22 ± 0.2 92 ± 0.3 23
CD11b+ 9 ± 0.1 10 ± 0.1 46 ± 0.2 13 ± 0.1
MHC-II+ 53 ± 0.1 83 ± 0.2 65 ± 0.3 98 ± 0.3
CD86+ 17 ± 0.2 72 ± 0.3 47 ± 0.2 87 ± 0.2
iNOS+ 2 ± 0.1 62 ± 0.1 4 ± 0.1 66 ± 0.1
aB16F10 murine melanoma or BMDC were infected with LMWT (B16F10-LMWT, BMDC-LMWT) or non-infected (B16F10-NI, BMDC-NI) for 24 hours.
bNO produced was measured in cell supernatants. Results are expressed as nmol of NO produced by 105 cells (mean ± SD, P<0.005) obtained with
triplicate samples.
cCell surfaces markers of B16F10 and BMDC infected or not with LMWT were analysed by FACS using the following antibodies: CD11c-PE, iNOS-FITC,
CD86-V450 and MHC-II-APC. Samples were acquired using FACSCanto flow cytometer. Results are expressed as the percentages of positive cell
(mean ± SD, P<0.005).
doi:10.1371/journal.pone.0117923.t001
independent experiments (P<0.05).B, Different phagocytic parameters analysed in melanoma and BMDC: phagocytic rates after incubation with [35S]-
labelled LM strains for 45 min (left plot). Radioactivity associated with cell lysates (CPM) was quantified in a β2 counter as the bacterial phagocytic rates.
Results are expressed as cpm of internalized bacteria (mean ± SD) (p< 0.05). Replication indexes (RI) analysis is shown in middle plot. RIs were calculated
as the ratio of the number of CFU at 16 h divided by the amount of CFU at 0 h. This parameter was considered as an indicator of bacterial growth. Results are
expressed as CFU (mean ± SD) (p< 0.05). The percentages of cytosolic fractions are shown in right plot after purification of phagosomal and cytosolic
fractions as inMaterial and Methods. Results are expressed as percentages of total internalized CFU in PNS (mean ± SD) (p< 0.05).C, Images correspond
to confocal microscopy examination of melanoma and BMDC infected with GFP-LMWT. GFP-LMWT (green channel) co-localize with MHC-II molecules (red
channel). Western blots correspond to the analysis in purified phagosomes for different MIIC markers: a/b stable MHC-II chains; Rab5a and LLO forms
bound to MHC-class II molecules. CFU values of purified phagosomes are shown below western blots.D, BMDC and B16F10 infected with LM strains or
non-infected (NI) were surface stained for the following markers: CD11c-PE, CD11b-FITC, F4/80-PE, CD40-PE, Gr-1-FITC and anti-MHC-II-APC. Samples
were acquired using FACSCanto flow cytometer and percentages of positive cells for each antibody are shown. Results are expressed as the mean ± SD of
triplicates (p<0.05). E, Samemelanoma cells infected with different LM strains or non-infected (NI) as in D for 24 hours. Supernatants were recovered,
filtered through 3 μm syringe to discard bacteria and the levels of pro-inflammatory cytokines MCP-1, TNF-alfa, IL-6, IL-10 or IL-12 were analysed using the
CBA kit (Becton Dickinson) by flow cytometry. Results were expressed as cytokine concentration (pg/ml of mean ± SD, P<0,05).
doi:10.1371/journal.pone.0117923.g001
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peritoneum (dark staining in peritoneum images of Fig. 2A) and melanoma colonization of the
white fat of peritoneal organs with no infiltration on the green fat (white fat images of Fig. 2A).
At 7 days, this melanoma model activated innate immune responses characterized by increased
percentages of splenic CD68+ macrophages (from 8,2% to 21,5% values) and follicular CD23+
DCs (from 12% to 39% values) but decreased percentages of CD56+ NK cells (from 26% to
10% values) observed in histological sections. T cell responses were also stimulated with in-
creased percentages of CD4+ (from 18% to 31% values) and CD8+ T cells (from 12,5% to 24%
values) (Fig. 2B). However, the significant growth of melanoma in the peritoneum after 7 days,
predicted that melanoma induced T cell responses were not tumoricidal but melanoma toler-
ant. In fact, after 15 days, there is an exaggerated melanoma growth in the peritoneum and me-
tastases in lungs and livers (liver metastasis images of Fig. 2A). The immune responses become
Fig 2. Listeria vaccination of melanoma shows a dual action, tumour regression by apoptosis and bacterial clearance. A, C57BL/6 female were
inoculated i.p. with 5 x 105 B16F10/mice (n = 5) for 7 (7-D) or 15 days (15-D). Mice were bled, sacrificed and treated for histological analysis as described in
Material and Methods. Images correspond to sections of peritoneum infiltrates or liver metastases.B, C57BL/6 female were inoculated i.p. with 5 x 105
B16F10/mice (n = 5) as in A for none (NT), 7 (7-D) or 15 days (15-D). Spleens from sacrificed mice (n = 5) were stained for histological analysis using different
antibodies as described inMaterial and Methods and images correspond to sections. Results are expressed as percentages of positive cells (mean ± SD)
(P< 0.05).C, C57BL/6 female were inoculated i.p. with 5 x 105 B16F10/mice (n = 5) for 7 days and next injected i.p. or not (NT) with 5 x 103 bc/mice of
different LM strains (LMWT or LMΔLLO) for 5 additional days. Mice were sacrificed, bled to collect sera and photographed before collecting melanoma and
lungs. Images correspond to the peritoneum of mice and the recovered melanoma. Plots correspond to measurements of diameters of collected melanoma.
Results are expressed as the mean ± SD (P< 0,05).D, Melanoma recovered from LMWT or LMΔLLO vaccinated mice or from non-vaccinated mice (NV) as in
C were analysed for early and late apoptosis by FACS according toMaterials and Methods after double staining with 7-AAD (IP labelled) and annexin V
(anexina labelled). Results are expressed as the percentages of late apoptotic cells, necrotic death, (Q2 area corresponding to double positive for 7-AAD and
annexin V cells) and the percentages of early apoptotic cells, programmed cell death (Q4 area corresponding to annexin V positive while 7-AAD negative
cells) (mean ± SD) (p< 0.05).
doi:10.1371/journal.pone.0117923.g002
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down regulated after 15 days (15-D images of Fig. 2B) and melanoma tolerance allowed tu-
mour growth without control and the death of most of the mice after 23 days. Since bacterial
vaccinations required at least 5 days for developing optimal innate and specific immune re-
sponses, we chose 7 days of melanoma induction to initiate the bacterial therapies, assuring
maximal physiological conditions of the mice.
LMWT therapy of melanoma using low doses of the pathogen (5 x 103 CFU/mice) caused
10-fold reductions on the melanoma size after 5 days post-challenged (LMWT bars in Fig. 2C).
LLO is required for melanoma regression since therapies with LMΔLLO strains caused no effect
on the melanoma size (LMΔLLO bars in Fig. 2C). Subcutaneous (s.c) inoculation of melanoma
into new-born pups followed by LMWT therapy (s.c) also reduced 6-fold the tumour size in dif-
ferent mice strains (S2 Fig., panel A and B). These results suggested that melanoma regression
seemed to occur also in the skin of immune tolerant post-natal mice of different gene back-
grounds. In the peritoneal carcinomatous B16F10 induced model, we also observed that reduc-
tion of the tumour size correlated with 10-fold reduction of melanoma adherence and mitotic
indexes (Table 2), indicating alterations on their cell cycle due to apoptosis or necrotic death.
To differentiate both types of death, we examined early and late apoptosis ratios in recovered
melanoma after vaccination with LMWT, LMΔLLO or no vaccination (NV). Direct LMWT infec-
tion of melanoma caused no change in late or early apoptosis in melanoma controls (CON-
TROL B16F10-NT plots of Fig. 2D). An increase in late apoptosis would correspond to
necrotic death, while increases in early apoptosis ratios would indicate programmed cell death
by stimuli such as cytokines. Melanoma recovered from LMWT vaccinated mice showed 2-fold
increases on early apoptosis, indicating that melanoma eradication occurred by programmed
cell death and not by necrotic death (MEL-recovered LMWT plots of Fig. 2D). Non-vaccinated
mice or LMΔLLO vaccinated showed no effect in melanoma cell cycle (MEL-recovered NV and
MEL-recovered LMΔLLO plots of Fig. 2D). Tumour regression also correlated with high LMWT
tropism for melanoma as we localized 45% of LMWT vaccination in the recovered melanoma
(legend in section d of Table 2). These results indicated that melanoma regression required LM
phagocytosis by tumour cells. Therefore, we next examined the different phagocytic and APC
capacities of the recovered melanoma. We observed 3-fold increases in the microbicidal abili-
ties of the recovered melanoma after LMWT vaccination since LMWT phagocytic rates and rep-
lication indexes decreased (LMWT-MEL in Table 2). We also detected an increase in the APC
competences since examination of cell surface markers verified that LMWT vaccination of mel-
anoma shifted the matured DC phenotype to a fully activated DC pattern in the recovered mel-
anoma (LMWT-MEL under APC markers column of Table 2), namely MHC-II+++CD11c+
+CD8α++CD40++CD83++CD86++CD11b+/-F4/80-. These results strongly predicted elimination
of the pathogen and amplification of T cell responses as melanoma transformed DC might
present antigens to CD4 or CD8 T cells.
Listeria vaccination of melanoma generates LLO specific CD8+ and
CD4+ T cells using recombinant LLO or peptides
To explore the immune responses generated by melanoma therapy with LMWT, we examined
the cell populations in the spleens of mice with LMWT therapy (black bars in Fig. 3A). First, we
observed that 96% of the inoculated LMWT localized in MHC-II+ cells, 56% CD11c+ DCs and
40% CD11b+ macrophages (GFP-LM black bars in Fig. 3A). These percentages were similar to
the cell populations observed in classical LMWT infections (GFP-LM grey bars in Fig. 3A).
These results confirmed LMWT tropism for APC. Second, melanoma therapy with LMWT in-
creased significantly the innate responses in the spleens since we observed amplifications on
the percentages of activated DCs, MHC-II+CD11c+CD40+CD83+CD86+ positive cells,
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CD11b+F4/80+ positive macrophages (data not shown) and NK cells of the tumorigenic
CD49b+ phenotype (black bars of Fig. 3A in left graphic). Third, we detected 200-fold increases
in the levels of MCP-1, TNF-alfa, IFN-gamma and IL-12, cytokines produced after melanoma
therapy with LMWT (black bars in Fig. 3B) compared to non-treated mice (white bars in
Fig. 3B). Melanoma therapy with LMWT also altered T cell responses, increasing the percent-
ages of CD8+ T cells and decreasing in the percentages of CD4+ T cells (CD4 and CD8 black
bars on left plot of Fig. 3A). The percentages of CD4 and CD8 T cells detected after melanoma
therapy with LMWT were similar to the percentages observed after a classical LMWT infection,
suggesting that T cells were Listeria driven (Fig. 3A). We next examined LLO specific T cell re-
sponses induced by melanoma therapy with LMWT since LLO seemed relevant in this melano-
ma model and in most reported Listeria-based immune-therapies [4, 5, 15, 24]. Therapy of
melanoma with LMWT stimulated higher 1.79 ± 0.03 percentages of recombinant LLO
(LLOrec)-specific CD8
+ cells and IFN-gamma producers and lower 0.4 ± 0.01 percentages of
Table 2. Listeria therapy produces modification of melanoma parameters.
Conditiona B16F10 CONTROL B16F10-NT B16F10-NT B16F10-NT
MEL-NV LMWT-MEL LMΔLLO-MEL
Adherenceb 100 ± 2 100 ± 2 5 ± 0.2 95 ± 0.2
Mitotix indexc 2 ± 0.01 2 ± 0.03 0.1 ± 0.02 1.9 ± 0.02
dPhago-R-LMWT 190 ± 11 192 ± 12 60 ± 3 180 ± 3
Phago-R-LMΔLLO 185 ± 9 185 ± 11 61 ± 2 188 ± 2
eRI-LMWT 70 ± 2 72 ± 0.32 12 ± 0.02 67 ± 0.2
RI-LMΔLLO 0.5± 0.01 0.5± 0.01 0.10± 0.01 0.6± 0.01
APC-markersf APC-markers APC-markers APC-markers APC-markers
CD11c+ 25 ± 0.1 22 ± 0.1 62 ± 0.2 23
CD11b+ 10 ± 0.1 10 ± 0.1 6 ± 0.1 10 ± 0.1
MHC-II+ 53 ± 0.1 53 ± 0.2 93 ± 0.3 53 ± 0.2
CD40+ 25 ± 0.1 5 ± 0.1 58 ± 0.1 5 ± 0.1
CD83+ 18 ± 0.1 8 ± 0.1 52 ± 0.1 8 ± 0.1
CD86+ 17 ± 0.1 7 ± 0.1 47 ± 0.1 7 ± 0.1
CD8alfa+ 0.3 ± 0.01 0.5 ± 0.01 72 ± 0.2 0.7 ± 0.01
F4/80+ 7 ± 0.1 2 ± 0.1 1 ± 0.01 2 ± 0.1
aB16F10 murine melanoma (B16F10-NT) were inoculated for 7 days into mice (n = 5). Mice were next vaccinated with LMWT (LMWT-MEL) or LMΔLLO
(LMΔLLO-MEL) for 5 days or non-vaccinated (MEL-NV) as described in Material and Methods. In some experiments we also used GFP-LMWT to follow LM
localization. Next, mice were sacrified and melanoma recovered from peritoneum (MEL). Melanoma size (Ø) was measured with a calliper and cells
disaggregated, passed through a filter and cultured for 7 days before analysis (P < 0.05).
bAdherence was evaluated as the percentage of culture cells adhered to the culture plates after 16 hours of culture. Results are expressed as the
percentage of cells (mean ± SD) (P < 0.05).
cMitotic index was calculated as the ratio of the number of cells set in culture at time 0 hours compared to time 16 hours (mean ± SD) (p < 0.05).
dRecovered melanoma were infected with LMWT or LMΔLLO for different times (0, 6, 16h) and phagocytic rates (Phago-R) were calculated as the number
of CFU at 0 h. Results are expresses as CFU x 100 (mean ± SD) (p < 0.05)
eReplication indexes (RI) analysis of recovered melanoma as in d. RIs were calculated as the ratio of the number of CFU at 16 h divided by the amount of
CFU at 0 h. This parameter was considered as an indicator of bacterial growth. Results are expressed as CFU (mean ± SD) (p < 0.05).
fAPC markers analysed in the recovered melanoma vaccinated or not (MEL-NV) by FACS using the following antibodies: CD11c-PE, CD11b-FITC, F4/80-
PE, CD40-PE, CD83-FITC, CD86-V450, anti-IAb-APC and CD8α-V450. Samples were acquired using FACSCanto flow cytometer and percentages of
positive cells for each antibody are shown. We also vaccinated with GFP-LMWT and observed that 45% of GFP-LMWT bacteria were localized in the
recovered melanoma (LMWT-MEL). Results are expressed as percentages of positive cells (mean ± SD of triplicates, P<0.005).
doi:10.1371/journal.pone.0117923.t002
Listeria Vaccination Causes Melanoma Regression
PLOS ONE | DOI:10.1371/journal.pone.0117923 March 11, 2015 11 / 18
LLOrec-specific CD4
+ cells and IFN-gamma producers (Fig. 3C). While a classical LM infection
after 5 days produced similar percentages of LLO190–201 specific CD4
+ and LLO296–304 specific
CD8+ T cell subsets and IFN-gamma producers, 1.05 ± 0.02 and 1.02 ± 0.01 percentages,
Fig 3. Efficiency of Listeria vaccination of melanoma is mediated by activation of LLOrec specific CD8+ T cells and inhibition of LLOrec specific
CD4+ T cells.C57BL/6 female were inoculated i.p. with 5 x 105 B16F10/mice (n = 5) for 7 days and next injected i.p. or not (NT) with 5 x 103 bc/mice of GFP-
LMWT strain for 3 additional days. Mice were bled and sacrificed. A, Immune cells plot (left) corresponds with spleens were homogenized and cell populations
were analysed by FACS. Results were expressed as the mean of the percentages of positive cells ± SD. LM growth plot (right) corresponds with spleen
homogenates examined for CFU in blood-agar plates. Results are expressed as CFU (mean ± SD) obtained with triplicate samples from three independent
experiments (P< 0,05).B, Levels of pro-inflammatory cytokines (MCP-1, TNF-alfa, IFN-gamma, IL-6, IL-10, IL-12) were analysed in sera of mice using the
CBA kit (Becton Dickinson) by flow cytometry. Results were expressed as cytokine concentration (pg/ml of mean ± SD, P<0,05).C, Spleen cells obtained
from homogenates after inoculation with melanoma B16F10 (5 x 105 cells/mice) for 7 days and vaccination with LMWT for 5 days (LMWT-MEL). Cells were
stimulated 5 h with recombinant LLO (0.1 μg/ml) in the presence of brefeldin A for intracellular cytokine staining. LLO-stimulated spleen cell surface was
stained for CD4 or CD8 and fixed and permeabilized using cytofix/cytoperm kit. Stimulated cells were surface stained for CD4 or CD8 using anti-CD4+FITC-
labeled or anti-CD8+APC-labelled and data gated to include histograms show the percentages of LLO-CD4+ and IFN-gamma producers (lower left) and LLO-
CD8+ and IFN-gamma producers (lower right) (R2 and R3 gates). Experiments were performed in triplicate and results are expressed as the mean ± SD
(p< 0.05).D, Spleen cells obtained from homogenates after inoculation with melanoma B16F10 pre-infected with LMWT (5 x 105 cells/mice) for 7 days. Cells
were stimulated 5 h with recombinant LLO (0.1 μg/ml) in the presence of brefeldin A for intracellular cytokine staining. Procedures were performed as in
C and results expressed as the mean ± SD (p< 0.05).
doi:10.1371/journal.pone.0117923.g003
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respectively (S3 Fig., panel A). Increased cytotoxic T cell responses seemed to explain the accel-
erate LMWT clearance in the spleens (LM growth plot in Fig. 3A). These results strongly sug-
gested that in vivo effects of melanoma therapy with LMWT implies the transformation of
melanoma into DC-like cells that stimulate LLO-specific T cell immune responses and caused
melanoma regression. To confirm this hypothesis we first infected in vitromelanoma with
LMWT and next i.p inoculated mice with these melanoma-infected cells. Five days post-inocu-
lation, we examined recombinant LLOrec-specific CD4
+ and CD8+ T cells producing IFN-
gamma. Similar to melanoma therapy with LMWT, we observed low 0.37 ± 0.02 percentages of
LLOrec-specific CD4
+ T cells and expanded 1.32 ± 0.03 percentages of LLOrec-specific CD8
+
T cells producing IFN-gamma (Fig. 3C). We also observed decreased 0.03 ± 0.01 percentages
of LLO190–201 specific CD4
+ and enhanced 1.76 ± 0.03 percentages of LLO296–304 specific CD8
+
T cells producing IFN-gamma (S3 Fig., panel B). We also evaluated immune responses to mela-
noma antigens using a B16F10 extract (MELext). Control melanoma inoculation produced
0.60 ± 0.02 percentages of MELext-specific CD4
+ and 0.65 ± 0.03 percentages of MELext-specific
CD8+ T cells producing IFN-gamma (legend of S3 Fig., panel C). Pre-infection of melanoma
with LMWT and inoculation into mice presented diminished 0.15 ± 0.01 percentages of
MELext-specific CD4
+, while no alteration of 0.65 ± 0.02 percentages of MELext-specific CD8
+
T cells (S3 Fig., panel C). These results suggested that LMWT therapy induces LLO, but not mel-
anoma-specific CD8+ T cell expansion; while decreases both LLO and melanoma-specific
CD4+ T cells. We confirmed the LLO specific CD8+ T cell expansion examining the frequencies
of LLO296–304 specific CD8
+ T cells (Table 3). Melanoma therapies with LMWT increased
LLO296–304 frequencies, from 1.75 values of a classical LM
WT infection to 2.25–2.50 values
(B16F10!LMWT and B16F10-LMWT!NV rows in Table 3). The increase in LLO specific
CD8+ T cell responses, correlated with regression of melanoma size observed in mice inoculat-
ed with melanoma pre-infected with LMWT or control melanoma (S3 Fig., panel D). This is a
widely common mechanism of several pathogenic bacteria used in cancer therapies [1, 4, 25].
In fact, other Listeria-based vaccines against breast cancer function by similar mechanisms [5].
Table 3. Frequencies of LLO296–304 specific CD8
+ T cells in spleens of B16F10 treated mice or non-
treated after LMWT therapy.
Therapy condition % Total dimer-CD8/LLO296–304 % Gated dimer-CD8/LLO296–304
NTa! LMWT 0.09 ± 0.01 1.75 ± 0.01
B16F10b ! LMWT 0.08 ± 0.02 2.53 ± 0.05
B16F10c-LMWT !NV 0.06 ± 0.01 2.25 ± 0.01
aC57BL/6 mice non-treated with murine melanoma were inoculated with saline i.p for 7 days and next
injected i.p with LMWT for 3 days as described in Materials and Methods. Splenocytes from mice treated
with LMWT were incubated with recombinant dimeric H-2Kb: Ig fusion protein (BD Biosciences) loaded with
LLO296–304 peptide. The staining cocktail contained the dimeric fusion protein loaded with the peptides,
CD8 and anti-IFN-gamma antibodies. CD8+ cells were gated for anti-IFN-gamma staining (% Gated dimer-
CD8) to calculate the frequencies of CD8+-LLO296–304. Results are expressed as percentages of triplicate
samples ± SD. P<0.05.
bB16F10 murine melanoma were inoculated i.p into C57BL/6 mice for 7 days and next injected i.p with
LMWT for 3 additional days as described in Materials and Methods. Splenocytes from mice were incubated
with recombinant dimeric H-2Kb: Ig fusion protein as in a. P<0.05.
cB16F10 murine melanoma pre-infected with LMWT was inoculated into C57BL/6 mice for 7 days as
described in Materials and Methods. Splenocytes from mice were incubated with recombinant dimeric H-
2Kb: Ig fusion protein as in a. P<0.05.
doi:10.1371/journal.pone.0117923.t003
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In conclusion, we envision the following model (Fig. 4) to explain the efficiency of our
LMWT vaccination. After the melanoma model is established in the mice for 7 days (step 1),
vaccination with low doses of pathogenic LMWT for 5 days (step 2) accessed the growing tu-
mour and infected these cells (step 3). LMWT infection of melanoma transformed them into
matured dendritic-like cells (MEL-DCm) (step 4) with APC competence and MIIC phago-
somes that degraded LLO to LLO processed forms LLO1–491 that allowed the generation of
LLO restricted CD4+ T cells and LLO restricted CD8 T cells. This Listeria-driven melanoma
transformation also generates exaggerated levels of the pro-inflammatory cytokines/chemo-
kines, MCP-1, TNF-α and IL-12 and high production of nitric oxide (NO), a well known lister-
icidal and tumour reducer molecule (step 5) [18]. This LM-driven melanoma transformation
also amplifies the activation of LLO296–304 restricted CD8
+ T cells (step 5) and blocks the stimu-
lation of LLO190–201 restricted CD4
+ T cells (step 5) [28]. The exaggerated levels of pro-
Fig 4. Model of action of our LMWT vaccination of melanoma. After LMWT vaccination of melanoma
induce mice, bacteria would infect the melanoma and transformed them into matured dendritic-like cells
(MEL-DCm) (step 4) with APC competence to process LLO and generate LLO189–201/CD4
+-restricted and
LLO91–99/CD8
+ restricted peptides. Melanoma transformation into DCm generates exaggerated levels of the
pro-inflammatory cytokines/chemokines, MCP-1, TNF-alfa and IL-12 (step 5), amplifies the activation of
LLO91–99/CD8
+-restricted T cells (step 5) and blocks the stimulation of LLO189–201/CD4
+-restricted T cells
(step 5). The exaggerated levels of pro-inflammatory cytokines and the amplification of LLO91–99/CD8
+-
restricted T cells producing high levels of IFN-gamma, strongly activated innate cells with tumoricidal
potential. The amplification of LLO91–99/CD8
+-restricted T cells would cause a LLO-driven tumour destruction
by programmed cell death (step 6). Also these LLO91–99/CD8
+-restricted T cells producing high levels of IFN-
gamma would activate the LMWT infected melanoma (MEL-Dm) to a fully activated state (MEL-DCma) that
might eliminate the pathogen (step 6) with the advantage of not requiring antibiotic treatment to destroy this
low dose of the pathogen used as therapeutic vaccine.
doi:10.1371/journal.pone.0117923.g004
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inflammatory cytokines and NO combined with the amplification of LLO296–304-restricted
CD8+ T cells producing high levels of IFN-gamma, strongly activated innate cells with tumori-
cidal potential such as CD11b+F4/80+ macrophages and specially, the NK tumoricidal pheno-
type cells CD49b+ and also other activated DC. But also, this dual immune action unbalanced
LLO-specific immune response towards a prevalence of LLO-specific CD8+ T cell subsets with
reduction of the LLO-specific CD4+ T cell subsets (step 5), as well as a general reduction on
CD4 T cell responses. This reduction on CD4 T cells, Listeria-specific or not, might break tu-
mour tolerance and in combination with the cytotoxic phenotypes of NK CD49b+ and LLO-re-
stricted CD8+ T cells [5, 6, 15, 17], would cause a LLO-driven tumour destruction by
programmed cell death (step 6). Also these LLO-restricted CD8+ T cells producing high levels
of IFN-γ would activate the LMWT infected melanoma (MEL-Dm) to a fully activated state
(MEL-DCma), with a TipDC phenotype of CD11c++MHC-II++CD8α++CD40++CD86++F4/80-
reported by several groups [29, 30], that might eliminate the pathogen (step 6) with the advan-
tage of not requiring antibiotic treatment to destroy this low dose of the pathogen used as
therapeutic vaccine.
The success of our LMWT vaccination of melanoma seemed exerted by matured DC or mel-
anoma transformed into DC (MEL-DCm or MEL-DCma) that strongly stimulate LLO-re-
stricted CD8+ T cells. This mechanism of action resembles the efficiency of a recent dendritic-
based vaccination against listeriosis that our group, as well as others [15, 26], reported using
DC loaded with LLO91–99 peptide and open up future dendritic-based vaccination protocols
for melanoma using Listeria peptides.
The carcinomatous peritonitis model of melanoma used in this study resembles at day 7,
stages II and III of human melanoma categories established in 2009 by the American Joint
Committee on Cancer [27] that corresponded with any size of tumour and no propagation to
other organs. Therefore, we propose that our LMWT vaccination of melanoma with low doses
of pathogenic bacteria might be a safe therapy for stages II and III of human melanoma, where
the only efficient treatment is currently surgery. Pre-clinical studies with melanoma patients
currently analyse this hypothesis (SYD and CAD unpublished results). In fact, we predicted
that LMWT vaccinations of cutaneous melanoma might transform melanoma cells into mature
and activated DCs and stimulate tumoricidal Listeria-specific CD8+ T cells and CD49b+ NK
cells as well as generate IFN-gamma and IL-12 cytokines effective against tumours as well as
killing the pathogen without topical antibiotic treatment. Here we proposed that targeting of
Listeria to melanoma and transforming melanoma into dendritic cells is a new mechanism of
vaccine efficacy that can be applied to attenuated Listeria vaccines expressing tumour antigens
proposed currently as therapies [19, 31].
Supporting Information
S1 Fig. Listeria does not transform other APC and non-APC cells into a dendritic cell phe-
notype. A, Kinetic analysis of J-774 macrophages (APC) and non-APC murine embryonic fi-
broblasts (MEF) or the ovarian CHO tumour cell lines infected with different LM strains
(LMWT, LMΔLLO). Results are expressed as CFU (mean ± SD) obtained with triplicate samples
from three independent experiments (P<0.05). B, Western blots of 30 μg of purified phago-
somes from J-774, BMDC, B16F10 melanoma for different MIIC markers: a/b stable MHC-II
chains; Rab5a and LLO1–491 forms bound to MHC-class II molecules. C, J-774 macrophages in-
fected with LM strains or non-infected (NI) were surface stained for the following markers:
CD11c-PE, CD11b-FITC, F4/80-PE, CD40-PE, Gr-1-FITC and anti-IAb-APC. Samples were
acquired using FACSCanto flow cytometer and percentages of positive cells for each antibody
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are shown. Results are expressed as the mean ± SD of triplicates (p<0.05).
(TIF)
S2 Fig. Vaccination of neonates with Listeria causes regression of subcutaneous melanoma.
2 days post-natal CD-1 (black bars) or C57BL/6 (grey bars) neonates were inoculated s.c with
1 x 105 B16F10/mice (n = 10) for 7 days and next injected s.c or not (NT) with 1 x 103 bc/mice of
different LM strains (LMWT or LMΔLLO) for 5 additional days. Mice were sacrificed, photo-
graphed before collecting melanoma and melanoma weighted and sized with a calliper. Panel A,
shows plots that correspond to measurements of diameters of collected melanoma. Results are
expressed as the mean ± SD (P< 0,05). Panel B, shows images of control melanoma (MEL-NT)
or melanoma vaccinated with LMWT (MEL-WT) inoculated s.c into C57BL/6 mice.
(TIF)
S3 Fig. Specific LLO immune responses in melanoma therapies with LM and tumour re-
gression. LLO specific immune responses were examined in splenocytes with LLO190–201 and
LLO296–304 peptides specific for CD4 or CD8 T cells in C57BL/6 mice [27], respectively, by in-
tracellular cytokine staining. Mice were injected with LMWT for 5 days without melanoma
challenge (panel A) or inoculated with melanoma pre-infected with LMWT (panels B and C).
Panel A, shows the percentages of LLO190–201 specific CD4 or LLO296–304 specific CD8 T cells
mice infected with LMWT for 5 days. Panel B, shows the percentages of LLO190–201 specific
CD4 or LLO296–304 specific CD8 T cells in mice inoculated with melanoma pre-infected with
LMWT. Panel C, shows specific melanoma immune response using a B16F10 extract (MELext)
and examining the percentages of MELext-specific CD4 or CD8 T cells of experiment of panel
B by intracellular cytokine staining. Inoculation of control melanoma showed 0.60 ± 0.01 per-
centages of MELext-specific CD4 T cells and 0.65 ± 0.01 percentages of MELext-specific CD8 T
cells. Panel D, shows the melanoma size of experiment of panel C, melanoma pre-infected with
LMWT (B16F10-LM-WT bars) or control melanoma (B16F10 bars). Results are expressed as
the mean ± SD. P<0.05.
(TIF)
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